









Markets
/
Stocks
/
nasdaq-tcrt
/

Alaunos Therapeutics Inc

TCRT

2.630USD

+0.290+12.39%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

5.80MMarket Cap

LossP/E TTM



Alaunos Therapeutics Inc

2.630

+0.290+12.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alaunos Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Alaunos Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 227 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alaunos Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

227 / 392

Overall Ranking

477 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Alaunos Therapeutics Inc Highlights

StrengthsRisks

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.00K.

Undervalued

The company’s latest PE is -1.16, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 107.75K shares, decreasing 54.73% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 30.06K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.64.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Alaunos Therapeutics Inc is 6.73, ranking 223 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.81

Change

-0.08



Financials

5.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.60

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Alaunos Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Alaunos Therapeutics Inc is 7.54, ranking 106 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.16, which is -133.13% below the recent high of 0.38 and -302.28% above the recent low of -4.67.

Score

Industry at a Glance

Previous score

7.54

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 227/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Alaunos Therapeutics Inc. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Alaunos Therapeutics Inc is 3.98, ranking 355 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.41 and the support level at 2.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.15

Change

-0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.040

Sell

RSI(14)

42.732

Neutral

STOCH(KDJ)(9,3,3)

24.286

Buy

ATR(14)

0.178

Low Volatility

CCI(14)

-81.453

Neutral

Williams %R

59.155

Sell

TRIX(12,20)

-1.020

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.550

Buy

MA10

2.678

Sell

MA20

2.788

Sell

MA50

3.286

Sell

MA100

3.068

Sell

MA200

3.035

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Alaunos Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.83%, representing a quarter-over-quarter increase of 1.14%. The largest institutional shareholder is The Vanguard, holding a total of 30.06K shares, representing 1.35% of shares outstanding, with 2.84% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Vieser (Jaime W.)

38.67K

+16.02%

Postma (Robert W.)

38.29K

+15.51%

Watermill Asset Management

33.33K

The Vanguard Group, Inc.

Star Investors

20.97K

BlackRock Institutional Trust Company, N.A.

21.35K

Geode Capital Management, L.L.C.

15.79K

-0.97%

Groenewald (Ferdinand)

10.78K

Jerman (Michael Allen)

4.18K

Hogue (Dale Curtis Jr.)

4.44K

+11.05%

Morgan Stanley Smith Barney LLC

1.68K

-3.33%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alaunos Therapeutics Inc is 1.81, ranking 280 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -1.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Alaunos Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.